CVS Health (CVS) reported $108.4 billion in revenue for the quarter ended September 2026, representing a year-over-year increase of 5.4%. EPS of $2.09 for the same period compares to $1.60 a year ago.
The reported revenue represents a surprise of +3.2% over the Zacks Consensus Estimate of $105.04 billion. With the consensus EPS estimate being $1.62, the EPS surprise was +29.01%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how CVS Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Medical membership - Total: 26.12 million compared to the 25.99 million average estimate based on five analysts. Medical membership - Insured - Commercial: 2.57 million versus the four-analyst average estimate of 2.47 million. Medical membership - Insured - Medicare Supplement: $1.16 billion versus $1.18 billion estimated by four analysts on average. Medical membership - Medicaid - Total: $2.32 billion versus the four-analyst average estimate of $2.31 billion. Revenue- Health Care Benefits: $36.86 billion versus $35.86 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +2.4% change. Net revenue- Health Services segment: $53.96 billion versus the five-analyst average estimate of $51.75 billion. The reported number represents a year-over-year change of +9.5%. Revenue- Pharmacy & Consumer Wellness Segment: $35.5 billion versus $35.51 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -2% change. Revenue- Health Care Benefits Segment- Services: $1.83 billion versus $1.86 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +5.2% change. Revenue- Health Care Benefits Segment- Net investment income: $455 million compared to the $432.13 million average estimate based on four analysts. The reported number represents a change of -11.3% year over year. Revenue- Pharmacy & Consumer Wellness Segment- Front store: $5.16 billion versus $5.16 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -0.5% change. Revenue- Pharmacy & Consumer Wellness Segment- Pharmacy: $29.73 billion compared to the $29.72 billion average estimate based on four analysts. The reported number represents a change of -2.3% year over year. Revenue- Health Care Benefits Segment- Premiums: $34.57 billion versus the four-analyst average estimate of $33.6 billion. The reported number represents a year-over-year change of +2.5%.View all Key Company Metrics for CVS Health here>>>
Shares of CVS Health have returned +5.8% over the past month versus the Zacks S&P 500 composite's -2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CVS Health Corporation (CVS): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).